PCM
ESPR

Prelude Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Prelude Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675K Buy
213,636
+197,966
+1,263% +$554K 0.05% 414
2026
Q1 		$42.9K Sell
15,670
-11,388
-42% -$36.1K ﹤0.01% 1134
2025
Q4 		$100K Sell
27,058
-38,269
-59% -$124K 0.01% 1185
2025
Q3 		$173K Sell
65,327
-200,261
-75% -$387K 0.01% 980
2025
Q2 		$261K Buy
265,588
+97,283
+58% +$97.4K 0.03% 673
2025
Q1 		$242K Buy
168,305
+48,630
+41% +$89.6K 0.02% 817
2024
Q4 		$263K Sell
119,675
-123,172
-51% -$287K 0.02% 859
2024
Q3 		$401K Sell
242,847
-28,042
-10% -$56.6K 0.02% 720
2024
Q2 		$601K Buy
270,889
+242,926
+869% +$571K 0.04% 464
2024
Q1 		$74.9K Sell
27,963
-1,828
-6% -$4.44K ﹤0.01% 1228
2023
Q4 		$89.1K Buy
+29,791
New +$38.6K 0.01% 1036
2018
Q1 		– Sell
-500
Closed -$33K – 1567
2017
Q4 		$33K Buy
500
+400
+400% +$21.5K ﹤0.01% 1023
2017
Q3 		$5K Sell
100
-100
-50% -$4.82K ﹤0.01% 1504
2017
Q2 		$9K Buy
+200
New +$7.36K ﹤0.01% 1409

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Prelude Capital Management's ESPR Position: Q2 2026 in Review

Prelude Capital Management increased its Esperion Therapeutics (ESPR) stake by 1,263% in Q2 2026, buying an estimated $554K and bringing the position to 213,636 shares worth $675K. The position accounts for 0.05% of the portfolio, ranked #414.

Prelude Capital Management first reported a position in ESPR in Q2 2017 and has held it in 14 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Prelude Capital Management held 213,636 shares of Esperion Therapeutics worth $675K as of Q2 2026.
  • Prelude Capital Management bought 197,966 Esperion Therapeutics shares in Q2 2026, an estimated $554K.
  • Esperion Therapeutics made up 0.05% of Prelude Capital Management's portfolio in Q2 2026, its #414 holding.
  • Prelude Capital Management first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 14 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.